We are live on ! Find out more
IKT icon

Inhibikase Therapeutics

22 hedge funds and large institutions have $2.49M invested in Inhibikase Therapeutics in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 4

3.7% less ownership

Funds ownership: 16.98% → 13.28% (-3.7%)

8% less funds holding

Funds holding: 24 → 22 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

84% less capital inflows, than outflows

Capital inflows: $260K | Capital outflows: $1.66M

Holders
22
Holders Change
-2
Holders Change %
-8.33%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
8
Reduced
4
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

IKT Hedge Fund Activity: Q2 2022 in Review

22 of the 5,965 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q2 2022, worth a combined $2.49M — down 61% from $6.33M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IKT and 4 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 8 added.

The largest buyer was Antara Capital, adding an estimated $98.3K. The largest seller was Kepos Capital, exiting entirely with an estimated $1.04M sold.

  • 22 institutional investors held Inhibikase Therapeutics (IKT) as of Q2 2022, down from 24 in Q1 2022.
  • Funds reported $2.49M of Inhibikase Therapeutics stock for Q2 2022, down 61% quarter-over-quarter.
  • 4 funds opened new Inhibikase Therapeutics positions in Q2 2022 and 6 closed out, a net change of -2 holders.
  • The largest Inhibikase Therapeutics buyer in Q2 2022 was Antara Capital, an estimated $98.3K added.
  • The largest Inhibikase Therapeutics seller in Q2 2022 was Kepos Capital, an estimated $1.04M sold.

Based on aggregated 13F filings for Q2 2022.